[
    [
        {
            "time": "",
            "original_text": "FIDELITY INVESTMENT TRUST增持泰格医药(03347)516万股，每股作价约116.70港元",
            "features": {
                "keywords": [
                    "FIDELITY INVESTMENT TRUST",
                    "增持",
                    "泰格医药",
                    "516万股",
                    "116.70港元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "FIDELITY INVESTMENT TRUST增持泰格医药(03347)516万股，每股作价约116.70港元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "在医药生物行业中，医药研发及生产外包(CXO)是高瓴重点布局的方向之一，包括药明康德、药明生物、泰格医药等行业龙头几乎全部被高瓴纳入怀中。",
            "features": {
                "keywords": [
                    "医药生物行业",
                    "CXO",
                    "高瓴",
                    "药明康德",
                    "药明生物",
                    "泰格医药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "CXO"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "在医药生物行业中，医药研发及生产外包(CXO)是高瓴重点布局的方向之一，包括药明康德、药明生物、泰格医药等行业龙头几乎全部被高瓴纳入怀中。",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "泰格医药(03347.HK)获FIDELITY INVESTMENT TRUST增持49.12万股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "FIDELITY INVESTMENT TRUST",
                    "增持",
                    "49.12万股"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "泰格医药(03347.HK)获FIDELITY INVESTMENT TRUST增持49.12万股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "净利润激变有玄机 泰格医药晋身行业龙头路漫漫",
            "features": {
                "keywords": [
                    "净利润",
                    "激变",
                    "泰格医药",
                    "行业龙头"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "净利润激变有玄机 泰格医药晋身行业龙头路漫漫",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]